• +1-646-491-9876
    • +91-20-67278686

    Search

    Phosphatidylinositol 45 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform-Pipeline Review H1 2017

    Phosphatidylinositol 45 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform-Pipeline Review H1 2017

    • Report Code ID: RW0001834448
    • Category Pharmaceuticals
    • No. of Pages 86
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Pipeline Review, H1 2017

    Summary

    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit gamma isoform is an enzyme encoded by the PIK3CG gene. It plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. It is involved in immune, inflammatory and allergic responses. It modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. It regulates T-lymphocyte proliferation and cytokine production.

    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) pipeline Target constitutes close to 16 molecules. Out of which approximately 16 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 10 and 1 respectively. Report covers products from therapy areas Oncology, Respiratory, Central Nervous System, Dermatology, Musculoskeletal Disorders, Ophthalmology and Undisclosed which include indications Solid Tumor, Chronic Obstructive Pulmonary Disease (COPD) , Colon Cancer, Lymphoma, Multiple Myeloma (Kahler Disease) , Breast Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM) , Ovarian Cancer, Pancreatic Cancer, Relapsed Chronic Lymphocytic Leukemia (CLL) , Arthritis, Asthma, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL) , Cystic Fibrosis, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL) , Primary CNS Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL) , Renal Cell Carcinoma, T-Cell Lymphomas and Unspecified.

    The latest report Phosphatidylinositol 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)
    - The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Overview
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development
    AstraZeneca Plc
    Infinity Pharmaceuticals Inc
    Johnson & Johnson
    Novartis AG
    PIQUR Therapeutics AG
    Rhizen Pharmaceuticals SA
    Taisho Pharmaceutical Holdings Co Ltd
    Verastem Inc
    Vertex Pharmaceuticals Inc
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles
    BVD-723 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    duvelisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IPI-549 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PQR-309 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PQR-514 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PQR-530 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptide to Inhibit PIK3CG for Cystic Fibrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RV-1729 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SF-2523 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit PI3K Gamma for Unspecified Indication - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small molecules to Inhibit Phosphoinositide 3-Kinase Gamma for Breast Cancer and Chronic Obstructive Pulmonary Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit PIK3CG for Chronic Obstructive Pulmonary Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPR-965 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TASP-0415914 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tenalisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products
    Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kinase Catalytic Gamma Polypeptide or Serine/Threonine Protein Kinase PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones
    Featured News & Press Releases
    May 18, 2017: Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association
    May 09, 2017: Infinity Provides Company Update
    May 03, 2017: Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma
    May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting
    Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma
    Apr 01, 2017: Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017
    Mar 02, 2017: Infinity Announces Presentation on IPI-549 at AACR Annual Meeting
    Feb 13, 2017: Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer
    Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication
    Jan 20, 2017: Infinity Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia Conference
    Jan 09, 2017: Infinity Provides 2017 Goals and Financial Guidance
    Dec 05, 2016: Verastem Presents Phase 2 DYNAMO Clinical Data at ASH 2016 Annual Meeting
    Nov 09, 2016: Infinity Announces Second Publication on PI3K-Gamma in Nature
    Sep 26, 2016: Infinity Presents Initial Clinical And New Preclinical Data On IPI-549 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    Sep 19, 2016: Infinity Announces Publication On PI3K-Gamma In Nature
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by Infinity Pharmaceuticals Inc, H1 2017
    Pipeline by Johnson & Johnson, H1 2017
    Pipeline by Novartis AG, H1 2017
    Pipeline by PIQUR Therapeutics AG, H1 2017
    Pipeline by Rhizen Pharmaceuticals SA, H1 2017
    Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017
    Pipeline by Verastem Inc, H1 2017
    Pipeline by Vertex Pharmaceuticals Inc, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AstraZeneca Plc
    Infinity Pharmaceuticals Inc
    Johnson & Johnson
    Novartis AG
    PIQUR Therapeutics AG
    Rhizen Pharmaceuticals SA
    Taisho Pharmaceutical Holdings Co Ltd
    Verastem Inc
    Vertex Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//phosphatidylinositol-45-bisphosphate-3-kinase-catalytic-subunit-gamma-isoform-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//phosphatidylinositol-45-bisphosphate-3-kinase-catalytic-subunit-gamma-isoform-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//phosphatidylinositol-45-bisphosphate-3-kinase-catalytic-subunit-gamma-isoform-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments